Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma (NHL)
About this trial
This is an interventional treatment trial for Non-Hodgkin's Lymphoma (NHL)
Eligibility Criteria
Inclusion Criteria: 18-60 years of age Risk group International Prognostic Index (IPI) 2 and 3 (age adjusted) Performance status: Eastern Cooperative Oncology Group (ECOG) 0-3 Patient's written informed consent Aggressive non-Hodgkin's lymphoma with CD20+ histology Exclusion Criteria: Already initiated lymphoma therapy Serious accompanying disorder or impaired organ function Bone marrow involvement > 25% Known hypersensibility to the medications to be used Known HIV-positivity Active hepatitis infection Suspicion that patient compliance will be poor Simultaneous participation in other trials Prior chemo- or radiotherapy for previous disorder Other concomitant tumour disease
Sites / Locations
- AK St. Georg
Arms of the Study
Arm 1
Experimental
R-CHOEP14 with 12x Rituximab
8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )